TrueBlue (TBI) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TrueBlue in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TBI shares.
View TBI analyst ratings or view top-rated stocks.

1 brokerages have issued twelve-month price targets for TrueBlue's shares. Their TBI share price targets range from $18.00 to $20.00. On average, they expect the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price.
View analysts price targets for TBI or view top-rated stocks among Wall Street analysts.

TrueBlue's stock was trading at $15.34 on January 1st, 2024. Since then, TBI shares have decreased by 29.4% and is now trading at $10.83.
View the best growth stocks for 2024 here.

TrueBlue saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 884,600 shares, a decline of 46.1% from the March 15th total of 1,640,000 shares. Based on an average daily trading volume, of 446,300 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.0% of the shares of the company are sold short.
View TrueBlue's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our TBI earnings forecast.

TrueBlue, Inc. (NYSE:TBI) released its quarterly earnings results on Wednesday, February, 21st. The business services provider reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.23. The business services provider earned $492.17 million during the quarter, compared to analysts' expectations of $472.53 million. TrueBlue had a positive trailing twelve-month return on equity of 2.39% and a negative net margin of 0.74%. The firm's quarterly revenue was down 11.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 EPS.

First Trust Dow Jones Select Microcap Index Fund holds 83,212 shares of TBI stock, representing 0.79% of its portfolio.

TrueBlue issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $392.0 million-$417.0 million, compared to the consensus revenue estimate of $425.3 million.

34 employees have rated TrueBlue Chief Executive Officer Patrick Beharelle on Glassdoor.com. Patrick Beharelle has an approval rating of 56% among the company's employees. This puts Patrick Beharelle in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other TrueBlue investors own include International Business Machines (IBM), Intel (INTC), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), The Goldman Sachs Group (GS), AT&T (T), Zynga (ZNGA), AbbVie (ABBV) and Amgen (AMGN).

TrueBlue's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.12%). Insiders that own company stock include A Patrick Beharelle, Carl Schweihs, Derrek Lane Gafford, Garrett Ferencz, Kim Harris Jones, Kristi A Savacool, Kristy A Fitzsimmons-Willis, Richard Christensen, Richard P Betori, Robert C Kreidler, Steven C Cooper, Taryn R Owen and William C Goings.
View institutional ownership trends.

Shares of TBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.